Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | PTGFR | P43088 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652408 | 0.91 | NOTUM (0.56) | NOTUMPTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL12584172 | 0.90 | HTR6 (0.50) | CHRM1NOTUMPTGER4PTGDRTBXA2R | |
| SCHEMBL12584024 | 0.89 | PTGER4 (0.48) | CHRM1NOTUMPTGER4PTGDRPTGER2 | |
| SCHEMBL12584263 | 0.88 | DHPS (0.47) | CHRM1PTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL987890 | 0.87 | PTGER4 (0.51) | NOTUMPTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL12900314 | 0.86 | FABP4 (0.50) | CHRM1NOTUMPTGER4PTGDRTBXA2R | |
| SCHEMBL12900317 | 0.86 | NOTUM (0.51) | NOTUMPTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL987514 | 0.86 | PTGER4 (0.46) | CHRM1PTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL12584205 | 0.85 | HCAR2 (0.48) | NOTUMPTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL22276249 | 0.84 | CYP11B1 (0.45) | NOTUMPTGER4PTGDRTBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-12-16 | — | — | US | disclosed |
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-2565191-B1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | ASTELLAS PHARMA INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| CN-102026961-A | Amide compound | ASTELLAS PHARMA INC | 2011-04-20 | — | — | CN | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | CHRM1 1240/4885NOTUM 2603/4885PTGER4 1/4885 |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | CHRM1 1240/4885NOTUM 2603/4885PTGER4 1/4885 |
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | CHRM1 1593/4885NOTUM 1255/4885PTGER4 1/4885 |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | CHRM1 1296/4885NOTUM 2645/4885PTGER4 1/4885 |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | CHRM1 1296/4885NOTUM 2645/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.